ALSO IN THIS MONTH'S ISSUE
Companies To Watch: AltruBio
: AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.
Genesis Of A Gene Therapy Manufacturing Giant
Dr. Timothy Miller is trying to build one of the world’s largest AAV gene therapy manufacturing facilities. The cofounder and CEO of Columbus, OH-based Forge Biologics has been scratching the regenerative medicine leadership itch for quite a while now.
VCs Breathe New Life Into Life Sciences Industrials
The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?
Creating A Culture of Innovation In Any Size Organization
A company’s size and culture play a large role in how it defines and executes innovation.
BEYOND THE PRINTED PAGE
Don’t Think Executing A Biopharma SPAC Is Easy9/20/2021
Michael Byrnes, CFO at eFFECTOR Therapeutics, provides a prequel to an upcoming two-part article in Life Science Leader, with some specific recommendations for executive teams on SPACs.
John C. Martin, A Much-Missed Mentor And Kronos Bio Board Member8/23/2021
Nobert Bischofberger, Ph.D., CEO of Kronos Bio, reflects on lessons learned from an important mentor and biotech icon.
Did You Expect It Would Take This Long To Go Public?7/19/2021
Laura Niklason, M.D., Ph.D., cofounder and CEO of Humacyte, explains some of the science of her regenerative medicines company so to be public via a SPAC.